How much funding has VirTech Bio raised?

VirTech Bio has disclosed $500K raised across 1 round.

Where is VirTech Bio headquartered?

VirTech Bio is headquartered in Beverly, US.

VirTech Bio

Beverly, US · Founded 2013 · Delaware corporation

Find your way into VirTech Bio

VirTech Bio develops OxyBridge, a human-derived hemoglobin-based oxygen carrier (HBOC) intended as a blood substitute for time-critical trauma patients in hemorrhagic shock and for pre-transplant donor organ perfusion. The product is aimed at military and civilian trauma care and organ transplantation, using an ultra-polymer design to deliver oxygen and maintain blood pressure without refrigeration.

Biotech Healthtech Medical Devices

Founders & leadership

Joseph TuckerExecutive

Matias VidalinCo-Founder & Executive Chairman

Dallas HackinCEO & Director, Medical Affairs

COL(R) Dallas Hack, MD, MPHinCEO & Director, Medical AffairsA retired Army colonel and physician, he directed the Combat Casualty Care Research Program at the US Army Medical Research and Materiel Command from 2008 to 2014 and later coordinated its Brain Health/Fitness Research Program, after serving as Command Surgeon for Multinational Force Iraq and Chief of Preventive Medicine Service at Walter Reed Army Medical Center. He has worked as an independent brain health consultant since 2015 and completed the I-Corps @ NIH program in 2019.

Reported raises · per SEC filings

Form D private placements

$500K disclosed across 1 round · 2016

▶$500KraisedJun 2016 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Joseph TuckerExecutive Officer
Matias VidalExecutive Officer, Director

Offering amount: $500K
Amount sold: $500K
Minimum investment: $50K
First sale: Jun 2016
Incorporated: Corporation, Delaware, 2013
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Vir6 shared keywordsVir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities. The company targets patients with unmet medical needs across these therapeutic areas.

LeadIQ3 shared keywordsLeadIQ offers a company search tool that provides B2B company profiles with data such as revenue, employee count, funding, and contact information to help sales teams find decision makers and build pipeline.

Companies competing with VirTech Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
Department of DefenseSpecial Operations Command	Phase II	2018	$1.8M
Department of DefenseSpecial Operations Command	Phase I	2018	$148.1K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2016	$239K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

VirTech Bio presenting at the Florida Venture Summit Dec. 6, 2022 - VirTech Biovirtechbio.com · Nov 2022

Frequently asked questions

What does VirTech Bio do?: VirTech Bio develops OxyBridge, a human-derived hemoglobin-based oxygen carrier (HBOC) intended as a blood substitute for time-critical trauma patients in hemorrhagic shock and for pre-transplant donor organ perfusion. The product is aimed at military and civilian trauma care and organ transplantation, using an ultra-polymer design to deliver oxygen and maintain blood pressure without refrigeration.
How much funding has VirTech Bio raised?: VirTech Bio has disclosed $500K raised across 1 round.
Where is VirTech Bio headquartered?: VirTech Bio is headquartered in Beverly, US.